Optic Neuritis Clinical Trial
Official title:
Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis
This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging biomarker predictive of retinal axonal loss and visual disability, 12 months after the occurence of a first clinical episode of optic neuritis.
Neurologists and Neuro-Ophthalmologists are in need for reliable and robust imaging
biomarkers enabling to predict retinal axonal loss and visual disability after clinical
episode of optic neuritis (ON). Length of optic nerve lesion measured on MRI may be one of
them.
The aim of our study is to measure the association between the extent of inflammatory
demyelinating process on optic nerve at the acute of ON and the retinal degenerative process
following optic nerve injury.
The investigators planned to include 50 patients suffering from a recent clinical episode of
ON.
Extent of demyelinating inflammatory process will be assessed by the length of optic nerve
double inversion recovery (DIR) hypersignal at the acute phase of ON.
The axonal degenerative process following optic nerve demyelinating injury will be assessed
by retinal atrophy measured on optical coherence tomography at 12 months after ON, by visual
disability measured on low vision contrast acuity scale and by microstructural quality
analysis of optic nerve measured on diffusion tensor imaging sequence of the optic nerve.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Unknown status |
NCT00261326 -
Simvastatin Treatment of Patients With Acute Optic Neuritis
|
Phase 3 | |
| Active, not recruiting |
NCT03963310 -
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
|
||
| Recruiting |
NCT03586557 -
Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis
|
N/A | |
| Recruiting |
NCT05487989 -
VIsual Pathways Model in Neuro-inflammatory Disorders
|
||
| Terminated |
NCT04131764 -
Diagnosis of ON With or Without MS or NMOSD
|
||
| Not yet recruiting |
NCT06453694 -
Efgartigimod for the Treatment of Acute Optic Neuritis
|
Phase 2 | |
| Completed |
NCT01962571 -
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
|
Phase 3 | |
| Recruiting |
NCT03302585 -
High-Dose Vitamin D Induction in Optic Neuritis
|
Phase 2 | |
| Recruiting |
NCT02886377 -
The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
|
N/A | |
| Completed |
NCT01987167 -
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
|
Early Phase 1 | |
| Completed |
NCT01451593 -
Neuroprotection With Phenytoin in Optic Neuritis
|
Phase 2 | |
| Completed |
NCT03630497 -
BN201 SAD MAD Study in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01337986 -
Ampyra for Optic Neuritis in Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Completed |
NCT01274702 -
Visual Reconstitution Therapy After Optic Neuritis
|
Phase 2 | |
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Withdrawn |
NCT00037115 -
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
|
Phase 4 | |
| Not yet recruiting |
NCT06389968 -
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT04257734 -
Epidemiologic and Clinical Characteristics of Optic Neuritis in China
|
||
| Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
| Completed |
NCT02939937 -
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
|
Phase 2 |